IQV News

IQVIA Receives WCG Pinnacle Award for Excellence in Site Relationships

IQV

(NYSE:IQV) RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--IQVIA (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries, has been honored with the WCG Pinnacle Award for Site Relationships in Professionalism and Communication. The award recognizes IQVIA’s commitment to building strong, collaborative partnerships with clinical trial sites worldwide. The award is based on feedback from over 12,000 par

IQVIA Announces Launch of Clinical Trial Financial Suite, a Next-Generation Platform for Integrated Financial Management

IQV

(NYSE:IQV) RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--IQVIA (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries, today announced the launch of its Clinical Trial Financial Suite (CTFS), an AI-enabled platform orchestrating all financial aspects of clinical trials. CTFS is designed to eliminate inefficiencies created by siloed systems and fragmented processes. In contrast to other industry of

IQVIA Announces CFO Transition in Early 2026

IQV

(NYSE:IQV) RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--IQVIA Holdings Inc. (“IQVIA”) (NYSE:IQV), a leading global provider of advanced analytics, technology solutions, and clinical research services to the life sciences and healthcare industries, today announced a planned leadership transition in its finance organization. Michael Fedock, currently Senior Vice President of Financial Planning & Analysis, has been appointed Executive Vice President and Chief Financial Officer, effective February 28, 2

September 2, 2025Leadership
Read more →

IQVIA and Flagship Pioneering Announce Strategic Collaboration to Accelerate the Development of Breakthrough Life Sciences Companies

IQV

RESEARCH TRIANGLE PARK, N.C. and CAMBRIDGE, Mass., Aug. 28, 2025 /PRNewswire/ -- IQVIA (NYSE: IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence, and Flagship Pioneering, the bioplatform innovation company, today announced a...

IQVIA and Veeva Announce Long-term Clinical and Commercial Partnerships and Resolution of All Disputes

IQV

Global partnerships to help customers improve clinical and commercial efficiency and effectiveness RESEARCH TRIANGLE PARK, N.C. and PLEASANTON, Calif., Aug. 18, 2025 /PRNewswire/ -- IQVIA (NYSE: IQV) and Veeva Systems (NYSE: VEEV) today announced global clinical and commercial...

IQVIA and Veeva Announce Long-term Clinical and Commercial Partnerships and Resolution of All Disputes

IQV

RESEARCH TRIANGLE PARK, N.C. & PLEASANTON, Calif.--(BUSINESS WIRE)--IQVIA (NYSE: IQV) and Veeva Systems (NYSE: VEEV) today announced global clinical and commercial partnerships and the complete resolution of all pending legal disputes. Under the terms of the long-term agreement, customers can use software, data, technology, and service offerings from Veeva and IQVIA together in a simple and efficient way. The global partnerships make it easy for customers to work with IQVIA and Veeva in key are

Kexing Biopharm Enters Strategic Partnership with IQVIA to Accelerate Global Expansion

IQV

SHENZHEN, China, Aug. 11, 2025 /PRNewswire/ -- Kexing Biopharm (688136.SH) has officially entered into a comprehensive strategic partnership with IQVIA(NYSE:IQV), a global leader in clinical research services, commercial insights and healthcare intelligence to the life sciences and...

IQVIA Health Research Space Wins 2025 MedTech Breakthrough Award for ‘Best Mobile App for Patient Engagement’

IQV

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--IQVIA (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries, has been selected as the winner of the “Best Mobile App for Patient Engagement” in the ninth-annual MedTech Breakthrough Awards program. IQVIA’s breakthrough Health Research Space platform allows direct-to-patient data collection and engagement with patient-facing mobile apps that

June 16, 2025Awards
Read more →

Nvidia Just Partnered With A Weight-Loss Giant, But It's Not About Pills

IQV

Nvidia teams up with Novo Nordisk and IQVIA to boost AI-powered drug development and streamline complex pharmaceutical workflows.

June 12, 2025
Read more →

IQVIA Unveils New AI Agents Built With NVIDIA To Speed Up Drug Discovery And Streamline Clinical Trials

IQV

June 11, 2025
Read more →

IQVIA Launches New AI Agents for Life Sciences and Healthcare

IQV

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--IQVIA (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries, unveils AI agents at GTC Paris. IQVIA’s new custom-built AI agents using NVIDIA technology are designed to enhance workflows and accelerate insights for life sciences. These live applications of agentic architectures illustrate how IQVIA AI and deep domain expertise are transformi

IQVIA Stock: Stuck In A Time Spiral - Value Play Or Bull Trap?

IQV

IQVIA stock may look ready for a breakout, but Adhishthana analysis reveals a complex time spiral that could last until 2030.

June 10, 2025
Read more →

Rein Therapeutics Doses First Patient in Phase 2 Trial for IPF Drug LTI-03

IQV

May 27, 2025
Read more →

JP Morgan Maintains Overweight on IQVIA Hldgs, Lowers Price Target to $177

IQV

May 19, 2025
Read more →

IQVIA Collaborates With Contract Research Organization Arm Of Sarah Cannon Research Institute, SCRI Development Innovations, To Transform Oncology Trials For Biopharma Partners Worldwide

IQV

May 16, 2025
Read more →

Deep Dive Into IQVIA Hldgs Stock: Analyst Perspectives (10 Ratings)

IQV

May 15, 2025
Read more →

Mizuho Maintains Outperform on IQVIA Hldgs, Lowers Price Target to $190

IQV

May 15, 2025
Read more →

Baird Maintains Neutral on IQVIA Hldgs, Lowers Price Target to $161

IQV

May 7, 2025
Read more →

UBS Maintains Buy on IQVIA Hldgs, Lowers Price Target to $185

IQV

May 7, 2025
Read more →

Barclays Maintains Equal-Weight on IQVIA Hldgs, Lowers Price Target to $165

IQV

May 7, 2025
Read more →

IQVIA Beats Q1 Earnings Expectations Despite Sector Uncertainty, Company Navigating Market Conditions 'Effectively' Says CEO

IQV

IQVIA reports Q1 EPS of $2.70 and revenue of $3.83 billion, raises 2025 sales outlook and highlights strong growth in analytics and R&D pipeline metrics.

May 6, 2025
Read more →

IQVIA Hldgs Affirms FY2025 Adj EPS Guidance of $11.70-$12.10 vs $11.83 Est; Raises FY2025 Sales Guidance from $15.72B-$16.13B to $16.00B-$16.40B vs $15.87B Est

IQV

May 6, 2025
Read more →

IQVIA Hldgs Q1 Adj. EPS $2.70 Beats $2.63 Estimate, Sales $3.83B Beat $3.77B Estimate

IQV

May 6, 2025
Read more →

Beyond The Numbers: 12 Analysts Discuss IQVIA Hldgs Stock

IQV

April 25, 2025
Read more →

HSBC Downgrades IQVIA Hldgs to Hold, Lowers Price Target to $160

IQV

April 25, 2025
Read more →

Truist Securities Maintains Buy on IQVIA Hldgs, Lowers Price Target to $216

IQV

April 10, 2025
Read more →

Barclays Downgrades IQVIA Hldgs to Equal-Weight, Lowers Price Target to $170

IQV

April 10, 2025
Read more →

Citigroup Maintains Neutral on IQVIA Hldgs, Lowers Price Target to $210

IQV

March 4, 2025
Read more →

JP Morgan Maintains Overweight on IQVIA Hldgs, Lowers Price Target to $232

IQV

February 18, 2025
Read more →

IQVIA Collaborates With NVIDIA To Combine IQVIA Connected Intelligence With NVIDIA AI Foundry To Help Transform Life Science Processes From R&D Through Commercialization

IQV

January 13, 2025
Read more →

Stephens & Co. Initiates Coverage On IQVIA Hldgs with Overweight Rating, Announces Price Target of $250

IQV

December 20, 2024
Read more →

Leerink Partners Reiterates Outperform on IQVIA Hldgs, Lowers Price Target to $248

IQV

November 19, 2024
Read more →

Peering Into IQVIA Hldgs's Recent Short Interest

IQV

November 5, 2024
Read more →

RBC Capital Reiterates Outperform on IQVIA Hldgs, Maintains $270 Price Target

IQV

November 5, 2024
Read more →

JP Morgan Maintains Overweight on IQVIA Hldgs, Lowers Price Target to $240

IQV

November 5, 2024
Read more →

Truist Securities Maintains Buy on IQVIA Hldgs, Lowers Price Target to $265

IQV

November 4, 2024
Read more →

Morgan Stanley Maintains Overweight on IQVIA Hldgs, Lowers Price Target to $265

IQV

November 4, 2024
Read more →

BTIG Maintains Buy on IQVIA Hldgs, Lowers Price Target to $260

IQV

November 1, 2024
Read more →

TD Cowen Maintains Buy on IQVIA Hldgs, Lowers Price Target to $255

IQV

November 1, 2024
Read more →

Deutsche Bank Maintains Buy on IQVIA Hldgs, Lowers Price Target to $265

IQV

November 1, 2024
Read more →

Barclays Maintains Overweight on IQVIA Hldgs, Lowers Price Target to $255

IQV

November 1, 2024
Read more →

Goldman Sachs Maintains Buy on IQVIA Hldgs, Lowers Price Target to $250

IQV

November 1, 2024
Read more →

RBC Capital Reiterates Outperform on IQVIA Hldgs, Maintains $270 Price Target

IQV

November 1, 2024
Read more →

Baird Maintains Neutral on IQVIA Hldgs, Lowers Price Target to $223

IQV

November 1, 2024
Read more →

Iqvia Holdings Exec Says Q4 Adj EPS Is Expected To Be Between $3.08-$3.18

IQV

October 31, 2024
Read more →

Iqvia Holdings Exec Says Expect Q4 Revenue To Be Between $3.9B-$3.95B

IQV

October 31, 2024
Read more →

IQVIA Forecasts 2024 Adjusted EPS Of $11.10-11.20 Compared To Prior Guidance Of $11.10-$11.30 And Consensus Of $11.21

IQV

October 31, 2024
Read more →

IQVIA Forecasts 2024 Revenues Of $15.35B-$15.4B Compared To Prior Guidance Of $15.425B-$15.525B And Consensus Of $15.471B

IQV

October 31, 2024
Read more →